Following this observation, we did a meta-analysis of mDCs and HLA-DR+CD4+ pDCs in PBMCs from prostate cancer (PC) and ovarian cancer (OvCa) patients and frequencies were compared to those identified in healthy donors (HD) (Supplementary Figure 2). The gene discussed is CD4; the disease is prostate carcinoma.